Human medicines European public assessment report (EPAR): Vysribli (previously Denosumab Intas), Vysribli, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised

New medicine to reduce triglycerides in adults with familial chylomicronaemia syndrome

Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, risankizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Dermatology, PIP number: P/0497/2022

Human medicines European public assessment report (EPAR): Terrosa, teriparatide, Date of authorisation: 04/01/2017, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Kinpeygo, budesonide, Date of authorisation: 15/07/2022, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Jayempi, azathioprine, Date of authorisation: 21/06/2021, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Aptivus, tipranavir, Date of authorisation: 25/10/2005, Revision: 44, Status: Authorised

Human medicines European public assessment report (EPAR): Praxbind, idarucizumab, Date of authorisation: 20/11/2015, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Jemperli, dostarlimab, Date of authorisation: 21/04/2021, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Zilbrysq, zilucoplan, Date of authorisation: 01/12/2023, Revision: 4, Status: Authorised